AnaValeria Castro

Prof. Dr. AnaValeria Castro


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
GHGrayson A. Herrgott
Grayson A. Herrgott
JSJames M. Snyder
James M. Snyder
RSRuicong She
Ruicong She
TMTathiane M. Malta
Tathiane M. Malta
TSThais S. Sabedot
Thais S. Sabedot
HNHoutan Noushmehr
Houtan Noushmehr
Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification of patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or monitoring. In this study, we analyze the DNA methylation levels in blood (serum and plasma) and tissue samples from 155 meningioma patients, compared to other central nervous system tumor and non-tumor entities. We discover DNA methylation markers unique to meningiomas and use artificial intelligence to create accurate and universal models for identifying and predicting meningioma recurrence, using either blood or tissue samples. Here we show that liquid biopsy is a potential noninvasive and reliable tool for diagnosing and predicting outcomes in meningioma patients. This approach can improve personalized management strategies for these patients.

25 February 2022 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
GHGrayson A Herrgott
Grayson A Herrgott
KAKaram P Asmaro
Karam P Asmaro
MWMichael Wells
Michael Wells
TSThais S Sabedot
Thais S Sabedot
TMTathiane M Malta
Tathiane M Malta
AnaValeria CastroAnaValeria Castro
AnaValeria Castro
Background: DNA methylation abnormalities are pervasive in pituitary neuroendocrine tumors (PitNETs). The feasibility to detect methylome alterations in circulating cell-free DNA (cfDNA) has been reported for several central nervous system (CNS) tumors but not across PitNETs. The aim of the study was to use the liquid biopsy (LB) approach to detect PitNET-specific methylation signatures to differentiate these tumors from other sellar diseases. Methods: We profiled the cfDNA methylome (EPIC array) of 59 serum and 41 plasma LB specimens from patients with PitNETs and other CNS diseases (sellar tumors and other pituitary non-neoplastic diseases, lower-grade gliomas, and skull-base meningiomas) or nontumor conditions, grouped as non-PitNET. Results: Our results indicated that despite quantitative and qualitative differences between serum and plasma cfDNA composition, both sources of LB showed that patients with PitNETs presented a distinct methylome landscape compared to non-PitNETs. In addition, LB methylomes captured epigenetic features reported in PitNET tissue and provided information about cell-type composition. Using LB-derived PitNETs-specific signatures as input to develop machine-learning predictive models, we generated scores that distinguished PitNETs from non-PitNETs conditions, including sellar tumor and non-neoplastic pituitary diseases, with accuracies above ~93% in independent cohort sets. Conclusions: Our results underpin the potential application of methylation-based LB profiling as a noninvasive approach to identify clinically relevant epigenetic markers to diagnose and potentially impact the prognostication and management of patients with PitNETs.

25 February 2021 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
MMMaritza S Mosella
Maritza S Mosella
TSThais S Sabedot
Thais S Sabedot
TSTiago C Silva
Tiago C Silva
TMTathiane M Malta
Tathiane M Malta
FDFelipe Segato Dezem
Felipe Segato Dezem
AnaValeria CastroAnaValeria Castro
AnaValeria Castro
Background: Distinct genome-wide methylation patterns cluster pituitary neuroendocrine tumors (PitNETs) into molecular groups associated with specific clinicopathological features. Here we aim to identify, characterize, and validate methylation signatures that objectively classify PitNET into clinicopathological groups.Methods: Combining in-house and publicly available data, we conducted an analysis of the methylome profile of a comprehensive cohort of 177 tumors (Panpit cohort) and 20 nontumor specimens from the pituitary gland. We also retrieved methylome data from an independent PitNET cohort (N = 86) to validate our findings.Results: We identified three methylation clusters associated with adenohypophyseal cell lineages and functional status using an unsupervised approach. Differentially methylated probes (DMP) significantly distinguished the Panpit clusters and accurately assigned the samples of the validation cohort to their corresponding lineage and functional subtypes memberships. The DMPs were annotated in regulatory regions enriched with enhancer elements, associated with pathways and genes involved in pituitary cell identity, function, tumorigenesis, and invasiveness. Some DMPs correlated with genes with prognostic and therapeutic values in other intra- or extracranial tumors.Conclusions: We identified and validated methylation signatures, mainly annotated in enhancer regions that distinguished PitNETs by distinct adenohypophyseal cell lineages and functional status. These signatures provide the groundwork to develop an unbiased approach to classifying PitNETs according to the most recent classification recommended by the 2017 WHO and to explore their biological and clinical relevance in these tumors.

29 August 2016 in Obesity
Verified
Journal Article
Open access
PDF file
JBJosiane L. Broussard
Josiane L. Broussard
AnaValeria CastroAnaValeria Castro
AnaValeria Castro
MIMalini Iyer
Malini Iyer
RPRebecca L. Paszkiewicz
Rebecca L. Paszkiewicz
IBIsaac Asare Bediako
Isaac Asare Bediako
CKCathryn M. Kolka
Cathryn M. Kolka
Objective: Insulin must move from the blood to the interstitium to initiate signaling, yet access to the interstitium may be impaired in cases of insulin resistance, such as obesity. This study investigated whether consuming a short‐ and long‐term high‐fat diet (HFD) impairs insulin access to skeletal muscle, the major site of insulin‐mediated glucose uptake.Methods: Male mongrel dogs were divided into three groups consisting of control diet (n = 16), short‐term (n = 8), and long‐term HFD (n = 8). Insulin sensitivity was measured with intravenous glucose tolerance tests. A hyperinsulinemic euglycemic clamp was performed in each animal at the conclusion of the study. During the clamp, lymph fluid was measured as a representation of the interstitial space to assess insulin access to muscle.Results: Short‐ and long‐term HFD induced obesity and reduced insulin sensitivity. Lymph insulin concentrations were approximately 50% of plasma insulin concentrations under control conditions. Long‐term HFD caused fasting plasma hyperinsulinemia; however, interstitial insulin concentrations were not increased, suggesting impaired insulin access to muscle.Conclusions: A HFD rapidly induces insulin resistance at the muscle and impairs insulin access under basal insulin concentrations. Hyperinsulinemia induced by a long‐term HFD may be a compensatory mechanism necessary to maintain healthy insulin levels in muscle interstitium.

Verified
Journal Article
Open access
PDF file
JSJuan Salazar
Juan Salazar
DPDaniela Pirela
Daniela Pirela
MNManuel Nava
Manuel Nava
Ana Valeria Castro RomeroAna Valeria Castro Romero
Ana Valeria Castro Romero
LALissé Angarita
Lissé Angarita
VBValmore Bermudez
Valmore Bermudez
Cardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and ω-6 fatty acids, integrated into four families: Lipoxins, Resolvins, Protectins, and Maresins. SPMs have generated interest in recent years due to their ability to promote the resolution of inflammation associated with the pathogeneses of numerous illnesses, particularly CVD. Several preclinical studies in animal models have evidenced their ability to decrease the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury via diverse mechanisms. Large-scale clinical trials are required to determine the effects of SPMs in humans. This review integrates the currently available knowledge of the therapeutic impact of SPMs in CVD from preclinical and clinical studies, along with the implicated molecular pathways. In vitro results have been promising, and as such, SPMs could soon represent a new therapeutic alternative for CVD.

16 October 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
JSJuan Salazar
Juan Salazar
CCClímaco Cano
Clímaco Cano
JPJose Perez
Jose Perez
Ana Valeria Castro RomeroAna Valeria Castro Romero
Ana Valeria Castro Romero
MDMaria Paula Diaz
Maria Paula Diaz
VBValmore Bermudez
Valmore Bermudez
Lifestyle modifications such as energy restriction and increased physical activity are highly effective in the management of obesity. However, adherence to these therapeutic approaches is poor. On the other hand, synthetic drugs used for obesity control are plagued by adverse effects. Despite these failures, adipose tissue is still an attractive therapeutic target for novel molecules, and thus, the characterisation of new and safer anti-obesity drugs is of significant interest. For this reason, in recent years, phenolic constituents of diverse plants have drawn much attention due to their health-promoting properties, opening new research lines related to brown adipose tissue activation and white adipose tissue (WAT) browning. The goal is to increase energy expenditure levels through thermogenic activity activation by multiple factors, like polyphenols. The suggested mechanisms by which polyphenols can modulate thermogenesis include Nor-epinephrine/Catechol-O-Methyl-Transferase (NE/COMT) inhibition, PPARγ co-activator alpha (PGC-1α)-dependent pathways activation, and mitochondrial biogenesis, among others. Although polyphenols such as quercetin, catechins, chrysin, luteolin, curcumin, resveratrol, gallic acid, and lignans have shown a positive effect on Non-Shivering Thermogenesis and WAT browning, most of them have only been active in murine models or in vitro systems, and their reproducibility in humans has to be proved. Probably in the future, an approach that includes these compounds as part of the nutritional regimen in conjunction with physical exercise, pharmacological and surgical therapy, would allow modulating a pathophysiological mechanism that is still elusive.